Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px
Document › Details

AstraZeneca plc. (8/17/17). "Press Release: Lynparza Receives Additional and Broad Approval in the US for Ovarian Cancer".

Region Region United States (USA)
Organisations Organisation AstraZeneca plc (LSE: AZN)
  Group AstraZeneca (Group)
  Organisation 2 FDA (US Food and Drug Administration)
  Group United States (govt)
Products Product Lynparza®
  Product 2 chemotherapeutic
Index term Index term AstraZeneca–Merck (US): cancer drugs, 201707– strategic oncology collab maximising combis of PARP + MEK inhibitors with PD-L1/PD1 medicines
Persons Person Bohen, Sean (AstraZeneca 201509– EVP Global Medicines Developent + CMO before Genentech + Stanford Univ)
  Person 2 Perlmutter, Roger M. (Merck (US) 2013– EVP + President of Merck Research Labs before Amgen 2001–2012)
     


   
Record changed: 2017-08-24

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

More documents for AstraZeneca (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px




» top